Chlamydia trachomatis orchestrates multifaceted host cell manipulation for immune evasion Authors: Deepthi Krishnan Nair Geetha, Paridhi Agarwal, Athulya Thiruvacholayil, Karthika Rajeeve Published: 2026 ABSTRACT AbstractChlamydia trachomatis is an obligate intracellular sexually transmitted human pathogen and a major cause of ocular and urogenital infections worldwide, causing significant reproductive and neonatal complications. Despite eliciting host immune responses, C. trachomatis infections frequently remain asymptomatic, contributing to silent epidemic that often progress to chronic disease. This paradox reflects the remarkable ability of the pathogen to intricately manipulate host cell survival pathways and immune signalling networks. This review synthesizes current knowledge of C. trachomatis pathogenesis and host–pathogen interactions, with a particular emphasis on immune evasion strategies, the implications of which might be effective for therapeutic and preventive approaches.Subject terms: Infection, Bacteriology Introduction Chlamydia trachomatis (C. trachomatis) is a highly prevalent Gram-negative, coccoid, obligate intracellular bacterium of the family Chlamydiaceae and the leading cause of bacterial sexually transmitted infection, with approximately 128.5 million new infections annually1. The prevalence of C. trachomatis infection is higher in the female population (3.1%) compared to the male (2.6%), with a higher incident rate in the region of America (4.5%), followed by Africa (3.8%) and South-East Asia (0.8%)2, partly reflecting more frequent screening of asymptomatic women. C. trachomatis genital infections are common among sexually active individuals of 14–25 years age, causing urethritis and cervicitis, and when untreated, can result in pelvic inflammatory disease (PID), which leads to infertility, ectopic pregnancy, and chronic pelvic pain as well as adverse maternal and neonatal complications3,4. C. trachomatis also infects the eye, resulting in trachoma, a significant cause of preventable blindness worldwide5. The pathogen is classified into three biovars—ocular, genital and lymphogranuloma venereum (LGV) based on disease manifestation and further subdivided into 19 serovars defined by variations in the major outer membrane protein (MOMP)6,7. Serovars A–C cause ocular trachoma; serovars D–K are associated with urogenital infections and reactive arthritis8; and serovars L1–L3 infect genital tissues and macrophages, leading to LGV7. Chlamydia exhibits a unique biphasic developmental cycle (Fig. 1), alternating between morphologically and functionally distinct forms: the infectious elementary body (EB, 0.25–0.3 µm) and the non-infectious replicating reticulate body (RB, 0.5–0.6 µm). When C. trachomatis encounters any unfavourable condition, such as deprivation of essential nutrients like amino acids, glucose, exposure to antibiotics, gamma-interferon (IFNγ), hormones, heat shock, exposure to adenosine, phage hyperinfection or co-infection with other viruses, the pathogen adopts a reversible persistent, viable non-cultivable aberrant form9–13. Persistence represents a major impediment to immune eradication and protective immunity, as the pathogen can rapidly resume active replication following the restoration of permissive host conditions (Fig. 1). Critically, defining the cues that control the EB–RB–EB transition offers a promising therapeutic opportunity, as perturbation of this tightly regulated process would cripple the bacterial lifecycle and facilitate immune-mediated clearance. Biphasic developmental cycle of C. trachomatis. During the early stage of infection, elementary body (EB) enter epithelial cells through type III secretion system and actin remodelling. Once internalized, EB differentiate into reticulate body (RB) within a membrane-bound inclusion, where they undergo binary fission, acquiring nutrients interacting with host cellular pathways, including vesicular trafficking and cytoskeletal components, while avoiding lysosomal degradation. In the later stage, RB re-differentiates into EB, which are subsequently released through epithelial cell lysis or extrusion. Under stress conditions, RB can form aberrant body, a reversible persistent state. Created in BioRender. Rajeeve, K. (2026) https://BioRender.com/aw8df69. The majority of Chlamydia infections are asymptomatic and therefore remain untreated, leading to recurrence14. Infections often persist for weeks to months, leading to fibrosis and tissue scarring through low-grade inflammation, although direct evidence in humans remains limited15,16. Natural immunity to chlamydial infection in humans appears to develop only after repeated exposures and is often partial and short-lived, further contributing to susceptibility to reinfection17–19. Recurrent infections and unresolved inflammation are major contributors to disease pathology, ultimately driving severe disease outcomes16. Although substantial advances have been made in defining the chlamydial intracellular survival, mechanisms of persistence and virulence repertoire, a fundamental paradox remains unresolved: How C. trachomatis provokes innate and adaptive immune responses yet frequently escapes eradication, leading to chronic and recurrent infection? This apparent contradiction indicates that Chlamydia does not merely evade immune detection but instead actively reprograms host immune signalling to uncouple inflammation from effective bacterial clearance while maintaining host cell viability. Despite its reduced genome of 1.0–1.2 megabases (Mb)20 and obligate intracellular lifestyle, the pathogen effectively communicates with the host by deploying a diverse array of virulence factors that promote intracellular survival21,22 and immune evasion23. At present, insight into these immune evasion strategies remains fragmented, varying across cell types, stages of infection and experimental models. In this review, we discuss how C. trachomatis virulence factors dynamically manipulate immune signalling in epithelial and immune cells, and examine how this immune modulation intersects with intracellular survival and tissue pathology to shape disease outcomes. Immune evasion at first contact C. trachomatis encounters multiple immediate innate immune barriers at the mucosal surface during early host entry, where the mucus layer lining the epithelium acts as both a physical and biochemical defence that critically determines whether infection is established or eliminated24. The female genital tract contains gel-forming mucin, such as MUC2, MUC4, MUC5AC, and MUC625, which may contribute to limiting epithelial access by trapping EB and reducing their viability. However, this proposed function is primarily inferred from mouse intestinal models where Muc2 completely excluded the bacteria from the inner mucosal layer, though direct evidence of the protective role of these mucins in human C. trachomatis genital infection remains limited26. In the genital tract, the acidic vaginal pH further compromises EB infectivity. In vitro models show that the metabolites produced by the commensal microbiota, particularly lactic acid creates a hostile microenvironment that suppresses chlamydial survival in a concentration and pH-dependent manner27. In parallel, early immune cell recruitment, including resident and transient lymphocytes, contributes to local immune surveillance during the initial stages of infection28,29. The mucus layer also serves as a matrix for immune molecules, antibodies and other defence molecules such as antimicrobial peptides (AMPs): human α-defensins (HADs or human neutrophil peptides, HNPs), human β-defensins (HBDs), and cathelicidin LL-37 near the epithelial surface30. Notably, LL-37 is produced and released by both epithelial cells and recruited neutrophils, showing strong anti-chlamydial activity31. C. trachomatis counteracts AMP-mediated defence through secreting proteases like cHtrA/ CPAF32,33 and deploying plasmid-encoded factors such as Pgp3, which sequesters host AMPs and facilitates ascending infection31,34. Beyond antimicrobial peptides, the complement system constitutes another major arm of innate immunity in host defence against C. trachomatis. Comprising over 30 soluble proteins, it is activated via the classical, lectin, or alternative pathways, leading to the generation of anaphylatoxins, opsonins, and membrane attack complexes mediating bacteriolysis35. The unique biphasic developmental cycle of C. trachomatis exposes the pathogen to complement-mediated immune challenges at two critical stages— extracellular EB prior to host cell entry and the intracellular stage in the infected host cells. Human serum contains complement proteins that bind to elementary bodies and promote rapid bacterial uptake, resulting in less than 1% bacterial survival36. Prior exposure-derived antibodies further enhanced phagocytosis of Chlamydia but did not correlate with antibody titres or seropositivity37. Chlamydial EB activate the host complement system, resulting in the deposition of C3 and C5 activation products on the bacterial surface, enhancing uptake by human monocytes, which promotes binding to B cells and bacterial clearance35,38. Structural and functional studies indicate that only a limited proportion of chlamydial EB displayed pore-like structures of lytic C5b-9 assemblies35. The highly cross-linked surface of chlamydial EB may act as a physical barrier, restricting access of the membrane-spanning domains of C5b-9 complex35. Moreover, in vitro studies demonstrate that during cell lysis and exit, the chlamydial protease, CPAF, can abrogate human serum-mediated anti-chlamydial activity via degradation of the complement proteins39. The membrane attack complex-mediated lysis is ineffective after intracellular replication is established, indicating that complement pressure has likely driven the evolution of immune evasion strategies in Chlamydia. In line with this, global protein analysis of complement deposition shows enrichment of Membrane Attack Complex (MAC) inhibitors such as vitronectin and clusterin, which block C5b-9 insertion and prevent effective lysis35. Moreover, MAC inhibitor CD59 is also observed to localise around the C. trachomatis inclusion40. These findings highlight the spatiotemporal ability of C. trachomatis to interfere with key complement components, weakening complement-mediated antimicrobial activity and promoting survival at the mucosal surface and infection of epithelial cells. Turning epithelial cells into frontline immune gatekeepers C. trachomatis infects mucosal epithelial cells of the urogenital tract and conjunctiva, which act as primary entry sites and active immune sensors41,42. Chlamydial EB bind host heparan sulfate proteoglycans (HSPGs) via outer membrane proteins such as OmcB and MOMP, stabilizing adhesion and promoting type III secretion system (T3SS)–dependent invasion of host cells43,44. Translocated effectors induce actin reorganization and facilitate bacterial internalization which then sequester into the membrane-bound inclusion45. Once internalized, the epithelial cells detect chlamydial pathogen-associated molecular patterns (PAMPs) such as LPS, lipoproteins, and peptidoglycan (PGN) via Toll-like Receptors (TLRs), triggering TNF-α and IL-6 production (Fig. 2)46,47. TLR2 and TLR4, enriched in the upper genital tract, play central role in sensing C. trachomatis48. Proposed TLR2 ligands include cHsp60 and Macrophage infectivity potentiator (Mip), though the precise activator remains unknown49,50. During productive infection, TLR2–MyD88 localizes around the inclusion to induce IL-8, whereas UV-inactivated, antibiotic-treated, or plasmid-cured C. trachomatis fail to activate TLR251,52. How TLR2, which is normally expressed at the cell surface, is recruited to the chlamydial inclusion remains unresolved, potentially occurring via endocytosed EB or peri-Golgi trafficking pathways. TLR2 can signal through heterodimerization with TLR1 or TLR6, enabling recognition of bacterial lipoproteins and activation of MyD88-dependent inflammatory pathways50,53. Several predicted chlamydial lipoproteins, including D381, D541, D067, and D775, have been shown to stimulate pro-inflammatory cytokine production such as IL-8 via TLR1/2 or TLR2/CD14 complexes53. Interestingly, TLR2-deficient mice exhibit markedly reduced oviduct and mesosalpinx pathology, underscoring its role in inflammation-driven tissue damage54. Moreover, very recent findings demonstrate that human genetic variation at the TLR1/TLR6/TLR10 locus can modulate cytokine responses to C. trachomatis, highlighting host genetic control of innate immune signalling55. An overview of epithelial pattern-recognition and signalling pathways engaged during C. trachomatis infection. During infection, multiple pattern-recognition receptors (PRRs), including Toll-like receptors (TLR2/1/6, TLR3, and TLR4–CD14) signal via MyD88 to activate NF-κB, driving pro-inflammatory cytokine production. Cytosolic NOD1 and NOD2 further contribute to NF-κB activation upon detection of bacterial components. While host sensing of chlamydial DNA by cGAS–STING signalling induces IRF3-mediated interferon production and ISG expression. Chlamydial effectors, including Cdu1 and CpoS, selectively modulate these pathways, shaping cytokine output from infected epithelial cells. Created in BioRender. Rajeeve, K. (2026) https://BioRender.com/x1ej9of. The role of TLR4 in chlamydial infection is debated due to the weak immunogenicity of chlamydial LPS and serovar-specific differences56. Chlamydial LPS is characterized by a genus-specific antigenic epitope comprising 3-deoxy-d-manno-2-octulosonic acid (Kdo) residues, including a unique α-Kdo linkage, along with a penta-acylated lipid A moiety57. It is speculated that this hypoacylated lipid A structure may contribute to its inability to activate the noncanonical inflammasome pathway58. For example, serovar E LPS signals via TLR4/CD14, whereas LGV1 LPS favours TLR2, likely due to differences in acylation patterns. Similarly, serovar L2 activates NF-κB through TLR4/CD14/MD2 in monocytes, unlike serovar E56. While TLR4 clearly contributes to immune cell signalling, its role in epithelial cells, the primary infection site, remains unclear. Although the ligand remains uncharacterised, C. trachomatis activates TLR3 signalling in human Sertoli cells, but this recognition is uncoupled from downstream NF-κB and IRF3 activation, resulting in a blunted pro-inflammatory response that promotes immune evasion and persistence59. In contrast, TLR3 KO murine models exhibited increased lymphocytic endometritis and salpingitis indicating its role in pathogen clearance60. The innate immune receptor TLR9, expressed exclusively on monocytes and dendritic cells, recognises single-stranded, unmethylated cytosine-phosphate-guanosine (CpG) sites on bacterial genomic DNA61. Even though C. trachomatis actively bypass fusion with endo-lysosomal vesicles, the genomic DNA of C. trachomatis can stimulate TLR9 signalling, triggering innate immune signalling, possibly during the transition of EB-RB-EB forms and under stress conditions like antibiotic challenges61. Genetic ablation of TLR9 does not alter the trajectory of primary C. trachomatis infection but enhances resistance to reinfection, indicating that TLR9 signalling may impair the development of protective immunity62. Supporting this notion, human studies have linked TLR9 polymorphisms to increased susceptibility to cervicitis and exacerbated Chlamydia-associated pathology63. Collectively, TLRs provide an early defence against C. trachomatis. In addition to TLRs, cytosolic pattern-recognition receptors such as NOD1 and NOD2 detect bacterial peptidoglycan and play a role in sensing C. trachomatis, despite its transient and limited peptidoglycan expression64,65. Functional studies showed C. trachomatis activates NOD1 in epithelial cells and fibroblasts, driving NF-κB and cytokine production64. A human genetic study further linked a NOD1 polymorphism (but not NOD2) with a higher risk of C. trachomatis-associated tubal infertility66. Engagement of germline-encoded pattern-recognition receptors (PRRs) at the inclusion membrane amplifies innate immune signalling pathways such as NF-κB, MAPK, IRF3 and cGAS-STING67,68, culminating in effector responses like inflammation, oxidative burst, autophagy or cell death. Chlamydia has evolved multi-layered sophisticated strategies to dampen each of these early immune barriers. STING, an ER-anchored PRR, mediates interferon responses by directly sensing chlamydial deadenylate cyclase dacA or indirectly through cGAS-detection of chlamydial DNA, which drives a cGAS–STING–IRF3–IFN-β axis69,70. In vivo, loss of cGAS or STING reduces IFN-β production, impairs bacterial clearance, decreases IFN-γ⁺ CD4⁺ T-cell recruitment, and exacerbates genital tract pathology71. Despite activation of these innate immune pathways, C. trachomatis suppresses type I IFN, blocks NF-κB activation and inactivates host immune effectors. The chlamydial deubiquitinase, Cdu1 inhibits NF-κB by stabilizing IκBα22, while the inclusion protein CpoS antagonizes STING signalling, limiting IFN-β production and preventing STING-mediated cell death72. Additionally, C. trachomatis induces ISG15, which dampens IL-6/IL-8 responses, reducing immune cell recruitment73. These strategies create a permissive intracellular niche and shape interactions with infiltrating immune cells. Beyond PRR-mediated cytokine responses, epithelial cells deploy cell-intrinsic degradative pathways as a second line of defence. The epithelial cells activate autophagy to alert the immune clearance in a stepwise manner. C. trachomatis coordinates inclusion maturation and expansion, employing multiple effectors to subvert both autophagic and endosomal clearance (Fig. 3). During infection, several EB can invade a single host cell and develop multiple inclusions, which further undergo homotypic fusion to form a prominent inclusion employing inclusion membrane protein (IncA)74. Once the inclusion membrane is established, it avoids interaction with late endosomes and lysosomes75, instead selectively fusing with ER- and Golgi-derived vesicles to acquire nutrients76,77. Furthermore, Rab GTPase localization studies show that early and late endosomal markers (Rab5, Rab7, Rab9) are excluded from inclusions, while recycling endosome (Rab4, Rab11) and ER-to-Golgi trafficking (Rab1, Rab6) markers are actively recruited, thereby diverting inclusions away from lysosomal fusion78. Interestingly, Cdu1 and Cdu2 are shown to secrete into the host cytosol, where they contribute to Golgi fragmentation79. Bacterial Incs, best known for their roles in invasion and intracellular growth, also reinforce inclusion membrane integrity, limiting autophagic recognition and protecting Chlamydia from endo-lysosomal immune surveillance80. These studies reveal a sophisticated mechanism by which the pathogen actively dismantles and reorganize the host’s cellular machinery to create a safe niche escaping immune attack. Overview of autophagy and apoptosis in C. trachomatis-infected host cell. Evading autophagy: Activation of TLR–MyD88/TIRAP/TRIF signalling drives NF-κB–dependent inflammation, while IFN-γ induces ubiquitination of the chlamydial inclusion, recruiting GBPs, LC3, and p62 for lysosomal targeting. However, Chlamydia trachomatis counters this through inclusion-associated deubiquitinases (Cdu1, Cdu2) and GarD; notably, Cdu1 stabilizes Mcl-1 to reinforce host cell survival. Concurrent recruitment of Rab GTPases maintains inclusion stability and trafficking, limiting lysosomal fusion and autophagic clearance. Blocking apoptosis: Chlamydia trachomatis sustains host cell survival by activating PI3K/AKT signalling via EphA2 and effectors such as Pgp3, TarP (through SHC1), and IncG, which also recruit 14-3-3β to sequester phosphorylated Bad. This enhances pro-survival factors (Mcl-1, cIAP2, BAG1, c-Myc) while inhibiting Bax/Bak-mediated mitochondrial permeabilization and cytochrome c release. Concurrent activation of Nrf2 and HIF-1α further promotes cytoprotective responses. Together, these mechanisms suppress apoptosis and autophagy, maintaining inclusion integrity and supporting intracellular replication. Created in BioRender. Rajeeve, K. (2026) https://BioRender.com/21akggf. Nevertheless, the host cells sense intracellular bacteria and secrete IFN-γ, which activates interferon stimulated genes (ISGs) via JAK-STAT pathway leading to the expression of Guanylate Binding Proteins (GBPs) and immunity related GTPase (IRG)81,82. Upon infection, pathogen-containing inclusions are ubiquitinated by host E3 ligases, and this signal is recognized by adaptor proteins such as p62, which recruit GBPs to mediate cell-autonomous defence83. C. trachomatis inhibits IFN-γ primed ubiquitination of its inclusion membrane, in contrast to Chlamydia muridarum84. Subsequent studies identified GarD, an inclusion membrane protein, as a key factor preventing IFN-γ–dependent ubiquitin tagging of the inclusion, thereby blocking the delivery of C. trachomatis into lysosomal-associated membrane protein 1 (LAMP1) compartment and protecting from ubiquitin-mediated destruction21. Moreover, Cdu1 is secreted onto the inclusion membrane, preventing recruitment of autophagy adaptors such as p62 and the autophagosomal marker LC3 (Fig. 3)85. Interestingly, knockdown of Cdu1 promotes recruitment of autophagy machinery to inclusions, yet this remains insufficient to inhibit bacterial growth85. This provides evidence that C. trachomatis employs multiple, partially redundant pathways to evade immune detection of the inclusion, such that blockade of any single route is inadequate for bacterial clearance. Thus, despite considerable progress, the precise mechanisms by which Chlamydia evades autophagy remain incompletely understood. While autophagy and vesicular trafficking shape early cell-intrinsic defence, programmed cell death represents a later immune safeguard that Chlamydia must actively suppress to preserve its intracellular niche86. Apoptosis shapes immune responses through a finely balanced combination of immunostimulatory and immunoregulatory signals. Dying cells release damage-associated molecular patterns (DAMPs) that alert the immune system to danger and promote antigen uptake by antigen-presenting cells, particularly dendritic cells87,88. These antigens are then processed and presented to activate adaptive immune responses, including cytotoxic T lymphocytes and natural killer (NK) cells88,89. At the same time, apoptotic cells are efficiently cleared in an anti-inflammatory manner through the release of immunosuppressive signals, preventing excessive inflammation and autoimmunity90. This coordinated balance allows apoptosis to contribute to effective immune surveillance while maintaining tissue homeostasis. Considerable effort has been taken to understand how Chlamydia inhibits host cell apoptosis. The bacterium inhibits both intrinsic and extrinsic pathways via multiple mechanisms (Fig. 3). The pathogen stabilizes host anti-apoptotic Bcl-2 family proteins and prevents the localization of Bak and Bax by actively inhibiting oligomerization. This prevents mitochondrial outer membrane permeabilization91,92, ensuring inhibition of downstream caspase activation and cleavage of poly (ADP-ribose) polymerase (PARP)93. Notably, this anti-apoptotic strategy is conserved among major Chlamydia species like C. trachomatis, C. muridarum, C. cavaiae, C. pneumoniae and C. psittaci94. During the early phase of infection, the effector TarP interacts with the adaptor protein SHC1, conferring early apoptosis resistance to infected cells95. The chlamydial inclusion serves as a communication hub by establishing contact with host organelles and intercepting vesicular traffic. C. trachomatis decorates the inclusion membrane with a range of Incs, primarily through the T3SS. Out of the several Incs, IncG is known to interact with 14-3-3-β and blocks apoptotic signalling by sequestering pro-apoptotic BAD protein96,97. This phosphorylated (inactive) state of BAD through the sustained activation of PI3K/Akt and MAPK/ERK signalling play a critical role in chlamydial intracellular survival. This persistent PI3K signalling is achieved by tyrosine kinase Ephrin type-A receptor 2 (EphA2) activation, which accumulates around the inclusion and contributes to the apoptosis resistance98. The PI3K/Akt and MAPK/ERK signalling cascade also drives the expression of anti-apoptotic and stress adaptive genes, Bcl-2-associated anthanogene 1 (BAG1), Cellular inhibitor of apoptosis 2 (cIAP2), and Myeloid cell leukemia 1 (Mcl-1)99–101. In addition, Cdu1 localized on the inclusion membrane facing the cytosol deubiquitinates Mcl-1, resulting in the blockage of cell death102. During the intracellular survival, the bacterium induces the stabilization of transcription factor hypoxia-induced factor 1 alpha (HIF-1α), leading to increased expression of Mcl-1 and consequent inhibition of intrinsic apoptosis103. Another effector, plasmid-encoded protein Pgp3, prevents apoptosis by activating PI3K/AKT and ERK1/2 pathways104. Pgp3 also promotes nuclear localization of Nuclear factor erythroid 2-related factor 2 (Nrf2), thus the Heme oxygenase-1 (HO-1) increment, facilitating apoptosis resistance105. Anti-apoptotic activity of Pgp3 also involves the regulation of Bax, Bcl2 and Caspase 3 by ERK activation via DJ-1 upregulation106. Pgp3 attenuates mitochondrial dysfunction and apoptosis via upregulation of high mobility group box-1 (HMGB1)107. Additionally, chlamydial outer membrane protein OmpA/MOMP was also reported to interfere with Bak activation, blocking apoptosis92. Together, these findings demonstrate how Chlamydia employs a multi-layered apoptosis firewall by recruiting effector proteins to maintain host cell survival, stabilize the inclusion and sustain its intracellular lifecycle. Further studies are needed to identify additional key players and elucidate the precise mechanisms involved. Host signalling pathways exploited by C. trachomatis to suppress cell death mechanisms can simultaneously enhance metabolic support, thereby ensuring prolonged intracellular survival, a perfect hideout from the host immune cells. Persistent activation of PI3K and MAPK pathways during infection promotes the upregulation of c-Myc108–110 and depletion of TP53111,112, facilitating metabolic reprogramming that supports bacteria. How C. trachomatis regulates these metabolic pathways in immune cells remains unexplored. c-Myc expression is known to repress immune-activating genes like CXCL10 and CCL5, inhibiting T cells, B cells and NK cells113,114. Moreover, high c-Myc is associated with high levels of CD47 and suppression of DAMPs, which will directly inhibit immune cell activity115,116. c-Myc expression reduces the MHC I molecule, thus preventing recognition by cytotoxic T cells117. Being a master regulator of metabolic genes, c-Myc can also alter immune cell metabolism, rendering it inactive. Similarly, depletion of P53 may impair IFN signalling and dysregulate cytokine/chemokine expression, thereby promoting an immune cold microenvironment in C. trachomatis-infected cells, as observed during Influenza A virus infection118. The cytokines IL-6 and IL-12, which play key roles in inflammation and NK cell activation, are transcriptionally regulated by p53; thus, p53 depletion may reduce their expression and decrease MHC class I levels, rendering Chlamydia trachomatis–infected cells less visible to cytotoxic T cells119–121. Although the anti-apoptotic and autophagy-evasion strategies of C. trachomatis have been studied in depth, it is increasingly evident that these signalling pathways also converge with immune evasion mechanisms, collectively supporting bacterial survival and persistence within the host. Further investigation will be important for elucidating the potential contribution of these metabolic and immune modulations of C. trachomatis survival within immune cells. At the later stages of Chlamydia development, the pathogen is reported to actively induce host cell death as part of its exit strategy, facilitating the release of infectious elementary bodies through two mutually exclusive pathways: host cell lysis or extrusion, independent of host cell type, to infect neighbouring cells122,123. During this final phase of the lifecycle, Chlamydia protein associating with death domain (CADD) is expressed, which colocalize with TNF receptor and induces cell death124. The induced cell death is notably caspase-independent125,126. Despite the strong apoptotic resistance exhibited during earlier stages of infection, this late cytotoxicity may reflect cumulative cellular stress induced by the bacterium itself or host immune responses127,128. Extrusion represents a non-lytic strategy in which C. trachomatis releases intact inclusions via myosin II–dependent actin contraction, preserving host cell integrity and providing a transient extracellular niche that enhances EB survival123,129. This conserved mechanism is predominant in human organoids, in contrast to the lytic exit observed in conventional cultures130. It is tempting to speculate that extrusion may function as a “Trojan horse,” facilitating immune evasion, promoting bacterial dissemination. Together, these studies establish epithelial cells as active immune gatekeepers rather than passive host targets during C. trachomatis infection. While epithelial cells mount antimicrobial responses through PRR signalling, interferon signalling, autophagy and vesicular trafficking pathways, Chlamydia counteracts these defences by stabilizing the inclusion, redirecting Rab and Golgi-dependent trafficking, and selectively suppressing autophagic and endo-lysosomal surveillance. Rather than inducing global immune suppression, C. trachomatis establishes a finely tuned balance that supports its survival while preserving host cell viability, ultimately reshaping the local cytokine milieu and downstream innate immune responses. Reprogramming immune cells into permissive niche Chlamydia-infected epithelial cells establish a pro-inflammatory secretome rich in IL-1α, IL-6, GM-CSF, and CXCR2 ligands (IL-8, CXCL1/2/5) to drive rapid neutrophil recruitment131. While IL-1 and IL-6 amplify and sustain this local inflammation, GM-CSF and CXCR2 ligands ensure neutrophil influx to the site of replication131–133. Under physiological conditions, neutrophils eliminate invading microbes through coordinated effector mechanisms, including chemotaxis, phagocytosis, production of reactive oxygen species (ROS), degranulation and the formation of neutrophil extracellular traps (NETs)134. Consistent with this canonical role, antibody-mediated neutrophil depletion during genital chlamydial infection increases the bacterial burden, underscoring the importance of neutrophils in early infection containment132. However, Chlamydia selectively dismantles key bactericidal pathways while preserving inflammation. A central mechanism underlying this uncoupling is mediated by CPAF, which cleaves the G protein–coupled receptor formyl peptide receptor 2 (FPR2), a critical sensor linking chemotactic cues to antimicrobial activation (Fig. 4)23. A primary endometrial organoid model further demonstrated that the chlamydial effectors CPAF and TepP suppress neutrophil recruitment to infected epithelial sites, highlighting an additional mechanism by which C. trachomatis interferes with immune cell trafficking at the mucosal interface135. Chlamydia trachomatis reprogrammes immune cells into a permissive niche. Upon infection, macrophages activate multiple innate sensing pathways: (1) the NLRP3 inflammasome triggers caspase-1 activation, leading to IL-1β and IL-18 maturation and gasdermin D–mediated pyroptosis; (2) Toll-like receptor (TLR)–MyD88 signalling activates NF-kB and IRF5, inducing pro-inflammatory cytokine responses; (3) IFN-γ promotes intracellular antimicrobial defence through induction of guanylate-binding proteins (GBPs), ubiquitin-mediated targeting and recruitment of LC3/p62, facilitating lysosomal degradation of bacterial compartments; (4) cytosolic DNA sensing via the cGAS–STING-TBK1 axis activates IRF3, resulting in type I interferon production. In parallel, Chlamydia infection induces host gene expression programmes that support antigen processing and presentation leading to MHC II- mediated activation of CD4+ T cells and linking innate sensing to adaptive immune responses. In human neutrophils, C. trachomatis deploys multiple effector proteins (eg., CPAF, Pgp3) to subvert host defences. These effectors neutralize antimicrobial peptides such as LL-37, and inhibit FPR2 signalling, resulting in modulation of ROS production, NF-kB activation, and cell death pathways (apoptosis/necroptosis). Consequently, neutrophil effector functions, including degranulation and NETosis, are suppressed. Overall, C. trachomatis activates multiple immune pathways while simultaneously modulating host responses to promote survival and persistence within a permissive intracellular niche. Created in BioRender. Rajeeve, K. (2026) https://BioRender.com/42iuvvc. Neutrophils recruited during C. trachomatis infection is not inert but is functionally decoupled from bacterial clearance, creating a broadly permissive niche that may facilitate co-infection by pathogens such as Neisseria gonorrhoeae23. This selective disarming extends to pgp3-mediated neutralization and sequestration of neutrophil antimicrobial peptide LL-3732–34. C. trachomatis infection profoundly alters neutrophil fate by delaying apoptosis and necroptosis through Mcl-1 and RIP3136. However, it is unclear whether neutrophils remain metabolically active, as its prolonged survival may shift their role from host defence to sustained inflammation and tissue damage, favouring chlamydial persistence. In line with this, it was shown that chlamydial CT135 activates the NLRP3 inflammasome via TLR2–MyD88 signalling to undermine neutrophil host defence, while infection-induced extracellular ATP acts as a DAMP that triggers P2X7R–NLRP3–dependent inflammasome driving endometritis independent of direct macrophage infection, establishing a paradigm of sterile inflammation137. In stark contrast to neutrophils, where chlamydial growth remains uniquely unaffected by IFN-γ-activated indoleamine 2,3-dioxygenase (IDO), macrophages leverage this axis to mount a robust cell-intrinsic defence138,139. Alongside IDO-mediated tryptophan depletion, macrophages utilize TLR2/4 signalling, ROS and iNOS induction, NLRP3 inflammasome activation and caspase-dependent pyroptosis, collectively to restrict bacterial replication50,53,140–143. Chlamydial inclusions in macrophages traffic along the endo-lysosomal and autophagy pathways, acquiring Rab7, LAMP1, and LC3 undergoing acidification and degradation, further reinforced by IFN-γ–induced guanylate-binding proteins and Perforin-2144–146. Macrophages further exert nutritional immunity through iron restriction and cytosolic surveillance via STING, a pathway activated by both chlamydial DNA and cyclic di-AMP, which trigger type I interferon responses that modulate bacterial control70,147,148. Despite this potent antimicrobial arsenal, macrophage responses are not uniformly sterilizing, as Chlamydia actively modulates macrophage polarization to permit persistence149. Consistently, metabolically active bacteria preferentially persist in M0/M2 macrophages with replication restricted in IFN-γ–activated (M1) cells. IL-4–stimulated (M2) macrophages provide a more permissive niche, with infection-induced IL-10 potentially promoting M0-to-M2 transition139. Studies using iPSC-derived macrophages demonstrated that Chlamydia efficiently replicates within these cells while avoiding lysosomal fusion149. Beyond bacterial control, infected macrophages also shape adaptive immunity by secreting TNF-α that induces T-cell apoptosis and suppresses IFN-γ production150. As professional antigen-presenting cells, macrophages process and present chlamydial antigens via MHC-II and cross-presentation through MHC-I to activate CD4⁺ and CD8⁺ T-cell responses, respectively151. Thus, macrophages simultaneously exert antimicrobial pressure while providing a niche for persistence and chronic inflammation, highlighting a critical yet unresolved balance between bacterial clearance and long-term infection. Dendritic cells (DCs) play a central role in bridging innate and adaptive immunity during Chlamydia infection by capturing, processing and presenting antigens to activate T cells. In the genital tract, mucosal DCs recognize chlamydial antigens through TLR2, leading to IL-12 production and migration to draining lymph nodes, where they prime naïve CD4⁺ T cells and drive protective Th1 polarization characterized by IFN-γ secretion152,153. However, C. trachomatis employs multiple mechanisms to disrupt DC function. By altering endosomal–ER–Golgi trafficking and endosome maturation, C. trachomatis impairs intracellular trafficking of MHC molecules, reducing MHC-I surface expression and limiting antigen cross-presentation to CD8⁺ T cells154. In parallel, it induces apoptotic cell death in both cDC1 and cDC2 subsets in the murine models through caspase-3/7 and Bak/Bax pathways, diminishing their capacity to activate CD8⁺ T cells155, a process that is further enhanced following uptake of chlamydial extrusion156. The infection upregulates immune checkpoint molecule PD-L1 in the murine genital tract, driven in part by type I IFN signalling, which engages PD-1 on T cells, suppressing T-cell activation, proliferation, and cytokine production157,158. Together, these studies illustrate a coordinated strategy adopted by the bacterium to evade adaptive immunity through dendritic cell apoptosis, suppression of antigen presentation, and immune checkpoint activation. Despite these immune evasion strategies, effective clearance of C. trachomatis relies heavily on CD4⁺ Th1-mediated immunity. IFN-γ- producing CD4⁺ T cells activate macrophage bactericidal functions and promote antimicrobial pathways that restrict intracellular chlamydial replication. Evidence from murine models demonstrates that athymic and MHC-II–deficient mice fail to resolve infection, whereas MHC-I deficiency or CD8⁺ depletion has minimal impact, underscoring the central role of CD4⁺ T cells in protective immunity159,160. Furthermore, adoptive transfer of antigen-specific CD4⁺ T cells confers protection, and a subset of these cells can acquire cytotoxic functions, directly lysing infected epithelial cells via perforin and granzyme B161. The Th1 response is a double-edged sword: while essential for bacterial clearance, persistent or dysregulated Th1-associated inflammation, characterised by cytokines such as IFN-γ, IL-12, TNF-α, IL-1β and IL-6, contributes to immunopathology, including fallopian tube scarring and infertility162. Clinical observations from women with upper genital tract pathology show elevated levels of these inflammatory mediators in endocervical samples, suggesting that prolonged immune activation rather than bacterial burden alone contributes to reproductive tract damage162. Consistent with this, distinct subsets of CD4⁺ T cells have been identified: protective populations that clear infection and non-protective subsets that drive tissue damage163. Mechanistic insights from murine models also highlight this functional heterogeneity of CD4⁺ T cells164. The balance between these populations is a key determinant of disease outcome. While Th1 responses remain central to bacterial clearance, studies in murine genital infection models indicate that Th17 responses can amplify genital tract inflammation and tissue damage through IL-17–mediated recruitment of neutrophils and enhancement of local inflammatory cascades164,165. In contrast, neutralization of the Th2 cytokine IL-4 had little effect on bacterial clearance in experimental models, suggesting a limited protective role166. Evidence further suggests that classical T-bet-dependent Th1 cells are dispensable for local clearance despite the essential role of IFN-γ in systemic survival, highlighting the functional heterogeneity and plasticity of CD4⁺ T-cells167. Although CD4⁺ T cells are considered the dominant mediators of adaptive immunity, other adaptive components contribute supportive roles. CD8⁺ T cells, although dispensable during primary infection, enhance vaccine-mediated protection in murine and primate models by producing IFN-γ and granzyme B168. However, vaccine-induced CD8⁺ T cells, accumulating in the genital tract, exhibit strong cytotoxic and cytokine responses169. In contrast, vaccines that induce CD4⁺ T-cell responses confer effective immunity, indicating that CD8⁺ T cells may play a supportive rather than a primary protective role in immunity to C. trachomatis169. Human studies support these observations and provide insights into clinical relevance. Consistent with the findings in murine models, human cervical biopsies from Chlamydia-positive women revealed CD4⁺ T cells dominate infection sites, with a strong Th1-skewed cytokine milieu170.These tissues also show increased expression of IFN-γ and TNF-α together with upregulation of MHC class II molecules, indicating active antigen presentation and local T-cell activation170. Women who resisted reinfection exhibited higher frequencies of IFN-γ producing Chlamydia specific CD4⁺ T cells, emphasizing the importance of durable memory171. Long-lived but compartmentalized tissue-resident memory CD4⁺ T cells within the genital mucosa provide rapid local immune responses upon reinfection and are considered key mediators of long-term protection172. Antigen-specific IL-4–producing CD4⁺ T cells have also been detected following C. trachomatis exposure in humans, indicating that Th2-type responses can arise during infection even though their contribution to protection remains unclear173. B cells and antibodies, while not independently protective, play important supportive roles in shaping adaptive immunity during C. trachomatis infection. In addition to antibody-mediated neutralization of extracellular EB, B cells can function as antigen-presenting cells that enhance optimal CD4+ T-cell priming174,175. Consistent with this, B-cell-deficient mice exhibit impaired T-cell responses and delayed bacterial clearance, underscoring the role of humoral immunity in supporting Th1-mediated protection176,177. Beyond antigen presentation and antibody production, B cells modulate immune responses through cytokine secretion. In particular, IL-10-producing B cells dampen Th1 responses, potentially contributing to bacterial persistence by limiting excessive inflammation178,179. Furthermore, mucosal antibody responses, particularly secretory IgA, may contribute to limiting reinfection at epithelial surfaces, although their protective efficacy is limited in the absence of robust cell-mediated immunity176,180. However, the precise contribution of B cells in protective versus pathological outcomes remains incompletely defined but may have implications for vaccine design, where coordinated humoral and Th1-mediated responses may be required for optimal protection. Despite the central role of Th1 CD4⁺ T cells in controlling C. trachomatis, adaptive immune outcomes vary widely, indicating that factors beyond intrinsic immune responses shape protection at mucosal sites. A key determinant is the cervicovaginal microbiome, which shapes the local immune environment and susceptibility to infection. Lactobacillus crispatus dominated communities support epithelial integrity and effective immune control, whereas anaerobic dysbiosis (e.g., Gardnerella, Prevotella) promotes inflammation yet permits persistence and ascension181–183. Microbial metabolites further influence infection; for example, indole-producing anaerobes can rescue C. trachomatis from IFN-γ–mediated tryptophan starvation184. This interplay is compounded by the gastrointestinal tract, which may act as a reservoir enabling autoinoculation and reinfection185. Together, the microbiome actively dictates whether infection is controlled or progresses to chronic disease. Although host–pathogen interactions within infected epithelial cells are well studied, a critical transitional phase in Chlamydia trachomatis infection remains poorly understood. After egress, infectious elementary bodies and secreted effectors are briefly exposed extracellularly, where they encounter immune cells. While the intracellular roles of major chlamydial effectors are well characterized (Table 1), their extracellular fate and functional relevance remain largely undefined. This gap is significant, as the extracellular phase represents a vulnerable bottleneck that may shape immune recognition, immune modulation, bacterial clearance and reinfection, offering potential therapeutic opportunities. Table 1Major C. trachomatis virulence factors and corresponding host defence pathways involved in infection, persistence and immune modulationChlamydia factorFunction/MechanismHost response/target pathwayOutcome/RelevanceReference/sMipActivates TLR2/TLR1/TLR6 via CD14-dependent signallingTLR–MyD88–ERKInduces TNF-α and IL-8; modulates inflammation at the early infection stage50GarDInhibits IFN-γ–mediated ubiquitination of the inclusion membraneUbiquitin pathway, LAMP1 recruitment, lysosomal targetingPrevents lysosomal destruction of the inclusion; promotes intracellular survival21Cdu1Deubiquitinase, stabilizes IκBα and anti-apoptotic Mcl-1p62, LC3, Mcl-1, IκB–NF-κBBlocks autophagosome recruitment and NF-κB activation; suppresses apoptosis and inflammatory signalling22,85,102IncGSequesters phosphorylated BAD via 14-3-3-βBAD–14-3-3 complex, PI3K/Akt–ERKBlocks mitochondrial apoptosis by preventing cytochrome c release and caspase-3 activation97Pgp3Activates PI3K/Akt and ERK1/2; upregulates Nrf2/HO-1 and DJ-1; modulates Bax/Bcl-2; Binds and sequesters LL-37PI3K–ERK–Nrf2Promotes mitochondrial integrity and resistance to apoptosis; blocks antimicrobial peptide function33,104–107OmpA / MOMPInterferes with Bak activationMitochondrial outer membrane permeabilizationInhibits intrinsic apoptosis92TarPInteracts with SHC1 adaptor early during infectionSHC1–ERKConfers early apoptosis resistance to infected cells95CPAFCleaves neutrophil FPR2, degrades complement factors C3 & B and antimicrobial peptide LL-37FPR2–MAPK–PI3KParalyzes neutrophil antimicrobial functions and ROS production, neutralise anti-chlamydial activity23,32,39DacASynthesizes cyclic di-AMP, activating STING and IFN-β productionSTING–IRF3Induces type I IFN and primes inflammasome responses69,148cHtrADegrades antimicrobial peptide LL-37LL-37 mediated defenceNeutralizes antimicrobial activity and delays neutrophil recruitment33,34CpoSAntagonizes STING signallingcGAS–STING–IRF3Suppresses IFN-β and prevents host cell death72CT135Activates NLRP3 inflammasome and ATP releaseNLRP3–IL-1αDrives sterile inflammation and tissue damage137CADDAssociates with TNF receptorDeath receptorPromotes caspase-independent cell death during exit124 Major C. trachomatis virulence factors and corresponding host defence pathways involved in infection, persistence and immune modulation Future perspective Despite substantial progress, Chlamydia trachomatis pathobiology remains incompletely understood at the mechanistic level. Notably, spontaneous clearance in untreated individuals suggests that sterilising mucosal immunity is biologically achievable, yet the antigen specificity and tissue localisation of the genital tract resident memory T cells remains unresolved. Decoding these correlates of protection might support rational vaccine design17. Patient-derived endocervical organoids integrated with autologous immune co-culture and single-cell multiomics will replace murine models with human-relevant translatable insights. Recent advances in genetic tractability of Chlamydia now enable systematic dissection on the role of chlamydial effectors in immune evasion, regulating innate sensors such as TLRs and cGAS–STING, and modulation of host cell survival pathways186,187. A central challenge lies in understanding how Chlamydia exploits host-derived metabolites, vesicular trafficking and membrane contact sites to meet its nutritional demands. The pathogen also dynamically manipulates autophagy and apoptosis, initially suppressing clearance while later exploiting these pathways for nutrient acquisition and prolonged host cell survival, mechanistically linking persistent infection to risk towards malignancy104. Dysbiois-derived indole directly attenuates IFN-γ-IDO-mediated tryptophan starvation, repositioning cervicovaginal microbiome as a biochemically active co-determinant of immune efficacy treatment outcomes181. Therapeutically converging anti-virulence and host-directed therapies, as well as next-generation mucosal vaccines eliciting durable, tissue-resident immunity, offer a more credible roadmap towards eliminating persistence and reinfection. Supplementary information Transparent Peer Review file Acknowledgements The authors gratefully acknowledge financial support from the BRIC–RGCB, Department of Biotechnology, the University Grants Commission (UGC), and the Council of Scientific and Industrial Research (CSIR), Government of India. The figures were generated using Biorender software. This study was supported by Department of Science and Technology – Science and Engineering Research Board (DST–SERB) SRG (Grant No. SRG/2021/001207), DST SERB- Promoting Opportunities for Women in Exploratory Research (DST SERB POWER) programme (Grant No. SPF/2021/000051), Government of India. Author contributions D.K.N.G. and K.R. conceived and designed the review. D.K.N.G., P.A., and A.T. conducted the literature search, generated the figures and wrote the first draft of the manuscript. K.R. critically revised the manuscript and obtained the funding. All authors have read and approved the final version of the manuscript. Peer review Peer review information Communications Biology thanks the anonymous reviewers for their contribution to the peer review of this work. Primary Handling Editor: Tobias Goris. A peer review file is available. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Supplementary information The online version contains supplementary material available at 10.1038/s42003-026-10403-9. References Associated Data Supplementary Materials Transparent Peer Review file